Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives $86.69 Consensus PT from Analysts

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Free Report) have received an average rating of "Moderate Buy" from the thirteen brokerages that are covering the firm, Marketbeat reports. One analyst has rated the stock with a hold rating and twelve have issued a buy rating on the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $86.69.

A number of equities analysts have recently commented on the company. Wells Fargo & Company raised their price objective on Ultragenyx Pharmaceutical from $72.00 to $75.00 and gave the stock an "overweight" rating in a report on Friday, August 2nd. The Goldman Sachs Group upped their price target on Ultragenyx Pharmaceutical from $67.00 to $76.00 and gave the stock a "buy" rating in a report on Friday, August 2nd. Cantor Fitzgerald restated an "overweight" rating and issued a $116.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, November 6th. Canaccord Genuity Group reaffirmed a "buy" rating and set a $121.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, November 12th. Finally, Wedbush upped their price objective on shares of Ultragenyx Pharmaceutical from $43.00 to $46.00 and gave the company a "neutral" rating in a research report on Friday, August 2nd.

Insider Activity

In related news, CFO Howard Horn sold 7,465 shares of the firm's stock in a transaction that occurred on Thursday, October 10th. The stock was sold at an average price of $52.76, for a total value of $393,853.40. Following the sale, the chief financial officer now owns 92,301 shares of the company's stock, valued at approximately $4,869,800.76. This trade represents a 7.48 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Emil D. Kakkis sold 20,000 shares of the stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $55.85, for a total value of $1,117,000.00. Following the completion of the sale, the chief executive officer now directly owns 2,223,985 shares in the company, valued at $124,209,562.25. This represents a 0.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 27,556 shares of company stock valued at $1,515,967. Company insiders own 5.80% of the company's stock.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

Large investors have recently made changes to their positions in the company. Sei Investments Co. increased its position in Ultragenyx Pharmaceutical by 0.9% in the 1st quarter. Sei Investments Co. now owns 65,996 shares of the biopharmaceutical company's stock valued at $3,081,000 after acquiring an additional 616 shares during the period. US Bancorp DE raised its stake in shares of Ultragenyx Pharmaceutical by 5.8% during the first quarter. US Bancorp DE now owns 7,143 shares of the biopharmaceutical company's stock valued at $334,000 after purchasing an additional 390 shares in the last quarter. ProShare Advisors LLC grew its position in Ultragenyx Pharmaceutical by 8.7% in the 1st quarter. ProShare Advisors LLC now owns 6,074 shares of the biopharmaceutical company's stock valued at $284,000 after buying an additional 486 shares in the last quarter. State Board of Administration of Florida Retirement System increased its stake in Ultragenyx Pharmaceutical by 2.5% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 87,673 shares of the biopharmaceutical company's stock valued at $4,093,000 after buying an additional 2,104 shares during the period. Finally, Vanguard Group Inc. increased its stake in Ultragenyx Pharmaceutical by 0.3% during the 1st quarter. Vanguard Group Inc. now owns 8,700,007 shares of the biopharmaceutical company's stock valued at $406,203,000 after buying an additional 26,575 shares during the period. Institutional investors and hedge funds own 97.67% of the company's stock.

Ultragenyx Pharmaceutical Stock Performance

Ultragenyx Pharmaceutical stock traded up $1.27 during midday trading on Wednesday, reaching $46.40. 641,624 shares of the company were exchanged, compared to its average volume of 787,596. The company has a market capitalization of $4.28 billion, a price-to-earnings ratio of -7.17 and a beta of 0.58. The firm's 50-day simple moving average is $53.80 and its 200-day simple moving average is $48.39. Ultragenyx Pharmaceutical has a 1 year low of $37.02 and a 1 year high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last released its earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) earnings per share for the quarter, topping the consensus estimate of ($1.45) by $0.05. Ultragenyx Pharmaceutical had a negative return on equity of 187.12% and a negative net margin of 106.93%. The firm had revenue of $139.49 million for the quarter, compared to the consensus estimate of $135.28 million. During the same period in the prior year, the business posted ($2.23) earnings per share. The firm's revenue for the quarter was up 42.3% compared to the same quarter last year. On average, analysts forecast that Ultragenyx Pharmaceutical will post -6.21 EPS for the current fiscal year.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.